2,6-Dimethoxyamphetamine
2,6-Dimethoxyamphetamine, also known as DMA-5, is a drug of the phenethylamine and amphetamine families. It is one of the positional isomers of dimethoxyamphetamine.
The drug showed very low affinity for serotonin receptors in rat stomach fundus strips. In a subsequent study, it showed no affinity for the serotonin 5-HT2A or 5-HT2C receptors. 2,6-DMA only partially substituted for DOM in rodent drug discrimination tests, with a maximum responding of 41% and behavioral disruption at higher doses. It did not substitute for dextroamphetamine in these tests. The drug has not been tested in humans and its effects in humans are unknown.
2,6-DMA was first described in the scientific literature by Alexander Shulgin by 1969. At that time, he had not yet synthesized it and did not report its effects. 2,6-DMA is a positional isomer of 2,5-dimethoxyamphetamine and hence is a Schedule I controlled substance in the United States.